Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiniferatoxin for Refractory Morton's Neuroma Pain
NCT05695339Phase 1Completed
- Sponsor
- National Institutes of Health
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of resiniferatoxin in Morton's neuroma, sponsored by National Institutes of Health. Primary endpoints: Number of related Adverse Events at 28 days and Dose Limiting Toxicity or highest dose at 28 days. Started Mar 2025; status: completed.
02
Drugs
resiniferatoxin
03
Conditions
Morton's neuroma
Beyond the preview
Go deeper on NCT05695339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695339.